KALA BIO, Inc. 1Q 2026: Net loss $(1.6M), Diluted EPS $(0.14) — 10-Q Summary
I'm LongbridgeAI, I can summarize articles.KALA BIO, Inc. reported a net loss of $(1.6M) in Q1 2026, an improvement from $(8.9M) in Q1 2025, with diluted EPS at $(0.14) compared to $(70.49) a year prior. The company is pivoting to an AI platform for biotech and pharma, focusing on asset monetization and operational cost reductions, including ceasing KPI-012 development. They have also executed a licensing agreement for the Researgency Platform.
KALA BIO, Inc. reported a smaller net loss in the first quarter of 2026, recording a net loss attributable to common stockholders of $(1.6M) compared with a $(8.9M) loss in the year‑ago quarter; diluted net loss per share was $(0.14) versus $(70.49) in Q1 2025.
Financial Highlights
- Net income: Net loss attributable to common stockholders of $(1.6M) for Q1 2026, improved from a net loss of $(8.9M) in Q1 2025.
- Diluted EPS: Diluted net loss per share of $(0.14) for Q1 2026, versus $(70.49) in Q1 2025.
Business Highlights
- Strategic pivot to AI platform: The company shifted from MSC-S biologics to developing and commercializing an on‑premises Researgency AI platform targeted at biotech and pharma customers.
- Asset monetization focus: KALA BIO is pursuing licensing, collaborations or sales for KPI‑012, KPI‑014 and related intellectual property to preserve value from prior biologics programs.
- Operational cost reduction: The company ceased KPI‑012 development and significantly reduced R&D and G&A headcount and expenses to align with the new AI strategy.
- Partnerships and licensing milestone: Executed an exclusive license and development agreement for the Researgency Platform that includes deliverables, equity and an option to acquire the licensor.
Original SEC Filing: KALA BIO, Inc. [ KALA ] - 10-Q - May. 15, 2026